The US Food and Drug Administration (FDA) on Friday approved nivolumab and hyaluronidase-nvhy, under the trade name Opdivo ...

TAMEST (Texas Academy of Medicine, Engineering, Science and Technology) names the five rising ... fundamental discoveries related to small cell lung cancer. Creating environmental and sustainable ...

Official trial name: CTIU2317/A082304/S2402: Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT Lung ...

In this edition of InnovationRx, medical debts will be erased from credit histories, this farm is doubling down on raw milk ...

North Carolina will now be represented in the U.S. House by 10 Republicans and four Democrats. Five new members will be sworn ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

Across faiths and across the globe, prominent individuals whose legacies are likely to continue to shape their ministries and ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, ...

The hope is that blocking both the PD1 and VEGF pathways can boost tumor immune cell biodistribution while minimizing VEGF-related adverse effects, all in the name ... non-small cell lung cancer.